Myozyme, also known as Alglucosidase Alfa (Intravenous Route)

Myozyme: Learn about Alglucosidase Alfa (Intravenous Route) for Pompe Disease Treatment. Discover how this powerful enzyme helps digest and absorb glycogen in individuals with Pompe disease. Find dosage forms and precautions for this intravenous medication.

Medriva Correspondents
Updated On
New Update

Myozyme: Understanding Alglucosidase Alfa (Intravenous Route)


Myozyme, also known as Alglucosidase Alfa (Intravenous Route), is a powerful enzyme used to treat infantile-onset Pompe disease. It is an injection-delivered medication available in powder form and is prescribed by a health care provider. This drug, which contains the human enzyme acid alpha-glucosidase, helps the individual digest and absorb glycogen. Those who suffer from Pompe disease are typically unable to produce enough of this enzyme on their own.

Brand Names

Myozyme is the US brand name for this drug, which also goes by the name Lumizyme. This product is not currently available in a Canadian brand name.



The active ingredient of Myozyme is Alglucosidase alfa, an enzyme that helps break down glycogen molecules. By providing this pharmaceutical enzyme, it can help those with Pompe disease, who are unable to produce the enzyme naturally, process their glycogen.

Dosage Forms


The only available form for Myozyme is an intravenous powder. This medication cannot be taken orally.

Before Use

Due to the powerful properties of this medication, it should only be taken under direct supervision of a healthcare provider, as it can cause side effects such as fevers, headache, chills, and fatigue, as well as more serious conditions such as seizures and anaphylaxis. Patients should not take this drug before discussing all risks and benefits with their doctor.

Chat with Dr. Medriva !